Anika Therapeutics (ANIK) revenue breakdown
By product, OEM Channel is the largest at 57% of fiscal 2025 revenue; Commercial Channel grew fastest, 15% a year over 3 years.
By region, UNITED STATES is the largest at 62% of fiscal 2025 revenue; Other Location grew fastest, 10% a year over 9 years.
Revenue by product
Fiscal years, as Anika Therapeutics reports them in its 10-K filings; fiscal 2025 total $113M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OEM Channel | — | — | — | — | — | — | $82M | $85M | $78M | $64M | 57% |
| Commercial Channel | — | — | — | — | — | — | $32M | $36M | $42M | $48M | 43% |
| Product | $103M | $108M | $106M | — | — | — | — | — | — | — | — |
| OA Pain Management | — | — | — | $103M | $83M | $85M | — | — | — | — | — |
| Joint Preservation and Restoration | — | — | — | $2M | $39M | $49M | — | — | — | — | — |
| Non-Orthopedic | — | — | — | $9M | $8M | $14M | — | — | — | — | — |
| Licensing, Milestone and Contract Revenue | — | — | — | $98,000 | — | — | — | — | — | — | — |
| Service | $447,000 | $6M | $24,000 | — | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Anika Therapeutics reports them in its 10-K filings; fiscal 2025 total $113M.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $84M | $93M | $85M | $90M | $103M | $114M | $84M | $87M | $82M | $70M | 62% |
| Europe | $11M | $12M | $12M | $15M | $14M | $20M | $17M | $17M | $19M | $22M | 20% |
| Other Location | $8M | $8M | $8M | $10M | $13M | $14M | $13M | $17M | $18M | $21M | 18% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ANIK.
Open ANIK in InvestinglyQuestions
Where does Anika Therapeutics make its money?
In fiscal 2025, by product: OEM Channel $64M, Commercial Channel $48M.
From Anika Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.